Michael Postow

44PUBLICATIONS
282CO-AUTHORS
Tumour immunologyPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Immunogenetics (incl. genetic immunology)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (44)

|Aug 13, 2026
Phase II trial of First-Line Axitinib Plus Nivolumab in Patients with Advanced Mucosal Melanoma.

|Jul 02, 2026
Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 years.

|Jun 25, 2026
Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma.

|May 04, 2026
Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastases.

|Mar 27, 2026
CD8 PET imaging with [89Zr]Zr-berdoxam-crefmirlimab in patients with solid tumors: the Phase II iCorrelate study.

Michael A Postow, Peter D Zang, Sumanta K Pal

|Mar 03, 2026
Where is the data? Delayed and chronic irAE surveillance and management after cessation of ICIs: expert insights from SITC on survivorship care and the need for long-term data.

Tessa F Flores, Emily S Tonorezos, Shailender Bhatia

Pageof 8

Frequent Collaborators

10 joint publications

Alexander Shoushtari

9 joint publications

Paolo A Ascierto

7 joint publications

Ryan Sullivan

7 joint publications

Jedd D Wolchok